Lisofylline
Alternative Names: A-802710; BL 194; CT-1501R; ProTecLatest Information Update: 28 Jun 2023
At a glance
- Originator Cell Therapeutics
- Developer DiaKine Therapeutics; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases
- Class Adjuvants; Chemoprotectants; Nonsteroidal anti-inflammatories; Radiation-sensitising agents; Small molecules; Xanthines
- Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Lysophosphatidic acid acyltransferase inhibitors; STAT4 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute lung injury; Chemotherapy-induced damage; Graft-versus-host disease; Mucositis; Neutropenia; Septic shock; Transplant rejection; Type 1 diabetes mellitus